JOURNEY MEDICAL CORP

DERM is the ticker symbol for Journey Medical Corporation, a pharmaceutical company focused on developing and commercializing dermatology products. Its shares trade on the Nasdaq Capital Market under that ticker. The company's portfolio includes treatments for acne, rosacea, and other skin conditions. DERM stock represents ownership in this commercial-stage specialty pharma business.

Recent price movement for DERM can be found in the latest quote data on this page, which shows current levels and the day's range. Because share prices for small-cap pharmaceutical companies can react sharply to product news, regulatory updates, or earnings releases, checking the page's live performance chart and recent-returns figures gives the most current view rather than relying on dated summaries.

Valuation for DERM typically involves comparing its market capitalization to revenue, earnings, or cash flow, and reviewing enterprise value relative to sales. Because Journey Medical is a smaller specialty pharma company, price-to-sales and price-to-book can be more informative than a P/E ratio if earnings are volatile or negative. The page's valuation section provides current multiples and comparisons to industry peers.

Shares of DERM may be available for extended-hours trading through participating brokers, though liquidity during pre-market and post-market sessions is often thinner than during the regular Nasdaq session. Prices in those windows can be more volatile. The page displays regular-session data by default; consult your broker for the specific extended-hours availability of DERM.

Journey Medical Corporation, the company behind DERM, has not paid regular cash dividends, as is common among commercial-stage pharmaceutical companies that retain capital for product development and commercialization. Any future dividend decision would depend on the company's financial position and board policy. The page's dividend section reflects the most recent distribution status for DERM.

Key risks for DERM include the commercial success of its dermatology products, regulatory decisions from the FDA, competition from generic and branded alternatives, and reliance on third-party manufacturers. As a smaller-cap company, it may also face financing needs, potential dilution, and greater share-price volatility. Reviewing Journey Medical's SEC filings provides detailed risk disclosures for DERM.